Linklaters and Baker & McKenzie have won lead roles advising on Novartis’ definitive agreement to divest its influenza vaccines business to Australian biotech firm CSL Limited (CSL), for $275m.
Your limit of 1 article in 30 days is up. Please login for full access or subscribe.
Corporate users - click here for simple access (no password needed).
For more information, please contact [email protected]
